You are viewing an incomplete version of our website. Please click to reload the website as full version.

VEGFR2 antibody (Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase))

Details for Product anti-KDR Antibody No. ABIN967481, Supplier: Login to see New
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

vegfr-2, KDR, 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR-2, VEGFR2, sVEGFR-2, Vegfr-2, CD309, FLK1, VEGFR, FLK-1, flk-1, FLK/KDR, flk1, flk1b, kdrb, si:busm1-205d10.1, si:ch211-254j6.1, si:ch211-278f ... show more
vegfr-2, KDR, 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR-2, VEGFR2, sVEGFR-2, Vegfr-2, CD309, FLK1, VEGFR, FLK-1, flk-1, FLK/KDR, flk1, flk1b, kdrb, si:busm1-205d10.1, si:ch211-254j6.1, si:ch211-278f21.4, wu:fc31a09, fk52c05, flk, kdr, kdra, vegfr2, vegfr4, vegr2, wu:fk52c05 show less
Mouse (Murine)
(510), (235), (135), (6), (3), (3), (3), (3), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1)
(462), (100), (22), (3), (2), (2), (1)
Clonality (Clone)
Monoclonal ()
This VEGFR2 antibody is un-conjugated
(34), (21), (15), (14), (12), (11), (3), (3), (3), (3), (3), (3), (3), (3), (1), (1), (1), (1), (1), (1)
Flow Cytometry (FACS), Immunohistochemistry (IHC), Western Blotting (WB)
(399), (232), (206), (113), (95), (94), (40), (24), (24), (20), (17), (16), (8), (6), (6), (2), (1), (1)
Pubmed 8 references available
Supplier Login to see New
Catalog number from supplier Login to see New
Quantity 0.5 mg
Shipping to United States ( )
Brand BD Pharmingen™
Immunogen Mouse Flk1 and human IgG1 fusion protein
Clone Avas 12alpha1
Isotype IgG2a, kappa
Characteristics 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Sodium azide is a reversible inhibitor of oxidative metabolism, therefore, antibody preparations containing this preservative agent must not be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
Purification The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
Alternative Name Flk1 (KDR Antibody Abstract)
Background The Avas 12alpha1 antibody reacts with fetal liver kinase 1 (Flk-1), a receptor protein tyrosine kinase closely related to CD117 (c-kit) and CD140a (PDGF Receptor alpha chain) of the immunoglobulin superfamily. Flk-1, also known as VEGF Receptor-2 (VEGF-R2), is a receptor for vascular endothelial growth factor (VEGF). It is expressed, at the mRNA and protein levels, on distinct sets of mesoderm during gastrulation and on endothelial cells in embryonic tissues. In vivo and in vitro studies indicate that Flk-1 is required for the embryonic development of vascular endothelial and hematopoietic cells.
Synonyms: VEGF-R2, Ly-73
Pathways RTK Signaling
Application Notes For immunohistochemistry application, we recommend to use purified Avas 12alpha1 mAb in our special formulation for immunohistochemistry.
Restrictions For Research Use only
Format Liquid
Concentration 0.5 mg/mL
Buffer Aqueous buffered solution containing ≤0.09 % sodium azide.
Preservative Sodium azide
Precaution of Use This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C
Storage Comment Store undiluted at 4° C.
Product cited in: Nishikawa, Nishikawa, Kawamoto et al.: "In vitro generation of lymphohematopoietic cells from endothelial cells purified from murine embryos." in: Immunity, Vol. 8, Issue 6, pp. 761-9, 1998 (PubMed).

Nishikawa, Nishikawa, Hirashima et al.: "Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages." in: Development (Cambridge, England), Vol. 125, Issue 9, pp. 1747-57, 1998 (PubMed).

Kataoka, Takakura, Nishikawa et al.: "Expressions of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells." in: Development, growth & differentiation, Vol. 39, Issue 6, pp. 729-40, 1998 (PubMed).

Hanahan: "Signaling vascular morphogenesis and maintenance." in: Science (New York, N.Y.), Vol. 277, Issue 5322, pp. 48-50, 1997 (PubMed).

Shalaby, Ho, Stanford et al.: "A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis." in: Cell, Vol. 89, Issue 6, pp. 981-90, 1997 (PubMed).

Millauer, Wizigmann-Voos, Schnürch et al.: "High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis." in: Cell, Vol. 72, Issue 6, pp. 835-46, 1993 (PubMed).

Shalaby, Rossant, Yamaguchi et al.: "Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice." in: Nature, Vol. 376, Issue 6535, pp. 62-6, 1995 (PubMed).

Background publications Quinn, Peters, De Vries et al.: "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 90, Issue 16, pp. 7533-7, 1993 (PubMed).

Catalog No. ABIN967481
Contact our Customer Service for availability and price in your country.

Order hotline:

  • +1 877 302 8632
  • +1 888 205 9894 (TF)